Vanguard Group Inc Aerovate Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.57 Trillion
- Q4 2024
A detailed history of Vanguard Group Inc transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,001,899 shares of AVTE stock, worth $2.37 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,001,899
Previous 1,151,873
13.02%
Holding current value
$2.37 Million
Previous $2.41 Million
10.3%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding AVTE
# of Institutions
83Shares Held
30.7MCall Options Held
186KPut Options Held
269K-
Ra Capital Management, L.P. Boston, MA9.19MShares$21.8 Million0.39% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA3.76MShares$8.91 Million0.81% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA2.24MShares$5.31 Million0.97% of portfolio
-
Atlas Venture Life Science Advisors, LLC1.8MShares$4.26 Million0.79% of portfolio
-
Braidwell LP Stamford, CT1.44MShares$3.41 Million0.21% of portfolio
About Aerovate Therapeutics, Inc.
- Ticker AVTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,448,100
- Market Cap $57.9M
- Description
- Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...